Selinexor, selective inhibitor of nuclear export, for non-Hodgkin lymphoma

At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, John Kuruvilla, MD, of Princess Margaret Cancer Centre, Toronto, Canada, discusses the early clinical activity of selinexor, an oral selective inhibitor of nuclear export (SINE) exportin 1 (XPO1) antagonist, for the treatment of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma and Richter’s transformation.

Share this video